AbbVie Inc.
https://www.abbvie.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AbbVie Inc.
Diversification Gains Momentum As Companies Look To Derisk China
Quietly but unambiguously, pharma firms are accelerating their diversification away from China and are now looking to other emerging markets for growth, a strategy that reflects increasing pressures from China's volume-based procurement scheme but also US-China tensions and other geopolitical risks.
Finance Watch: Earnings Season Brings Job Cuts, Even At Big Pharma
Restructuring Edition: Even big pharma companies are not immune from workforce reductions. BMS and Sanofi joined that ranks of Evotec, CureVac and BenevolentAI in cutting jobs. Also, Vaxxinity will de-list and Hepion winds down its NASH trial, among other strategic updates.
First Generic Of B+L’s OTC Switch Lumify Approved For Dr. Reddy’s Amid Patent Infringement Battle
Canadian firm received approval from FDA for NDA submitted in May 2023 for Lumify Preservative Free. A month earlier, FDA approved Dr. Reddy's ANDA submitted in July 2021 for an equivalent of Lumify’s formulation, brimonidine tartrate 0.025% ophthalmic solution.
Digital Health Roundup: US FDA’s ‘Idea Lab’; Philips’ Roy Jakobs On AI Draft Framework; Apple Watch
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights key interviews with Philips’ CEO Roy Jakobs on NAM’s framework on AI, BD’s CTO Beth McCombs R&D initiatives and HSS spine co-chair Sheeraz Qureshi on his vision for integrating AI tech. Hannah Daniel discusses the FDA’s new initiative to create an idea lab for medical device use at home and a new feature on the Apple Watch to help people with Parkinson's disease overcome freezing gait.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Luminera
- Mavupharma
- Pharmacyclics, Inc.
- Stemcentrx, Inc.
- Syndesi Therapeutics SA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice